Tricuspid Training Series: Evaluation and Management of Patients with Severe Tricuspid Regurgitation

Why It Matters

The episode underscores that timely surgical intervention can curb right‑ventricular decline, a critical factor as the elderly population expands. Understanding these nuances helps clinicians improve outcomes and informs device manufacturers about market demand for advanced valve technologies.

Key Takeaways

• Severe tricuspid regurgitation incidence rising with aging population
• Transcatheter options remain limited; surgery still gold standard for many
• Early referral improves outcomes and reduces right‑heart failure risk
• Multidisciplinary heart team essential for patient selection and timing
• Emerging imaging techniques refine surgical planning and postoperative monitoring

Pulse Analysis

Severe tricuspid regurgitation (TR) has moved from a neglected footnote to a front‑line concern in cardiovascular practice. Once thought to be a benign by‑product of left‑sided disease, recent registries reveal that up to 1.5 % of adults over 65 develop clinically significant TR, and the condition is now linked to a two‑fold increase in mortality when left untreated. The aging demographic, combined with rising rates of atrial fibrillation and chronic pulmonary hypertension, fuels this surge. Consequently, clinicians are pressed to recognize TR early, before irreversible right‑ventricular remodeling sets in.

Management strategies for severe TR are evolving, but surgery remains the cornerstone for most patients with favorable anatomy. The 2024 ACC/AHA valve guidelines now recommend isolated tricuspid valve repair or replacement within six months of symptom onset for patients with right‑ventricular dilation and preserved pulmonary pressures. Transcatheter tricuspid interventions, while promising, are limited to high‑risk cohorts and still lack long‑term durability data. Advanced imaging—3‑dimensional echocardiography, cardiac MRI, and CT‑derived annular sizing—has sharpened surgical planning, reducing operative times and postoperative complications.

The clinical shift has direct repercussions for the medical‑device market and health‑care systems. Surgeons’ renewed confidence in open repair drives demand for specialized prostheses, suturing devices, and peri‑operative monitoring tools, creating a projected $850 million global market by 2030. Meanwhile, manufacturers of transcatheter systems are accelerating trials to expand indications and prove cost‑effectiveness. For hospitals, integrating a multidisciplinary heart‑team workflow—cardiologists, cardiac surgeons, imaging specialists, and heart‑failure experts—can streamline referrals, improve resource allocation, and ultimately lower readmission rates for this high‑risk population.